Corporate Presentation

April 2024

Nasdaq: AEMD

www.AethlonMedical.com

FORWARD LOOKING STATEMENTS

This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as

contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which

are subject to the "safer harbor" created by those sections. All statements other than statements of historical fact contained in this presentation

are forward-looking statements, including, without limitation, statements regarding: Aethlon's ability to enroll patients in Aethlon's ongoing and

planned clinical trials; Aethlon's ability to successfully complete Aethlon's clinical trials and achieve the endpoints for the trials, or any future

clinical trials with Aethlon's Hemopurifier® or to successfully develop and commercialize the Hemopurifier®; Aethlon's ability to demonstrate

the removal of nanoparticles (NPs), extracellular vesicles (EVs) and their associated cargo with the Hemopurifier®; the potential synergistic use

of the Hemopurifier with chemotherapy, immunotherapy and targeted agents; Aethlon's ability to successfully demonstrate the benefit of

Aethlon's Hemopurifier® in the organ transplant setting; and Aethlon's ability to raise additional capital and to maintain Aethlon's listing on the

Nasdaq Capital Market (Nasdaq); and Aethlon's ability to establish and maintain collaborations. These forward looking statements are subject

to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of Aethlon's clinical trials and

preclinical research with the Hemopurifier® in the organ transplant setting; Aethlon's ability to enroll patients in Aethlon's ongoing and planned

clinical trials on a timely basis, or at all; Aethlon's dependence on Aethlon's CROs and other third parties; Aethlon's ability to manufacture

Aethlon's Hemopurifiers®; Aethlon's ability to obtain regulatory approvals within the timeframes expected, or at all; complications associated

with product development and commercialization activities; the size and growth of the market(s) for the Hemopurifier® and the rate and degree

of market acceptance thereof; Aethlon's ability to raise additional capital; Aethlon's ability to remain listed on Nasdaq; and Aethlon's ability to

attract and retain key management, and members of Aethlon's board of directors. In light of these risks and uncertainties, and other risks and

uncertainties that are described in the Risk Factors section of Aethlon's Form 10-K filed with the Securities and Exchange Commission (SEC) on

June 28, 2023, subsequent filings with the SEC on Forms 10-Q and 8-K, and other filings that Aethlon makes with the SEC from time to time

(which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and

Aethlon's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak

only as of the date of this presentation and are based on information available to Aethlon as of the date of this presentation, and Aethlon

undertakes no duty to update such information except as required under applicable law. All third-party brand names and logos appearing in

this presentation are trademarks or registered trademarks of their respective holders. Any such appearance does not necessarily imply any

affiliation with or endorsement of the Company.

2

Investment Highlights

  • Developing novel, patented Hemopurifier blood purification device
    • Early clinical trials have demonstrated virus and EV (extracellular vesicles, which include exosomes) clearance both in vitro and in patients
  • The FDA has designated the Hemopurifier® as a "Breakthrough Device"
    • The treatment of individuals with advanced or metastatic cancer
    • The treatment of life-threatening viruses that are not addressed with approved therapies
  • Focused on multiple therapeutic targets in cancer, viral disease and organ transplantation
    • Solid tumors failing anti-PD1
    • COVID-19
    • Proof-of-conceptstudies underway in organ transplantation
  • U.S. and international clinical trials
    • Planned oncology trials in Australia and in India
    • Open COVID-19 trial in India
  • Broad patent portfolio
  • Experienced management team

3

The Aethlon Hemopurifier®

FDA Designated "Breakthrough Device" In Viral And Oncology Indications

• Safely administered in 164 Hemopurifier sessions in 38 patients1

• Proprietary, patented technology

• Has demonstrated clearance of life- threatening viruses

• Designed to clear tumor-derived EVs, and their associated cargo (Oncology)

1. Aethlon clinical safety database

4

The Hemopurifier® Is Designed To Capture Viruses And Extracellular Vesicles From A Patient's Blood Via Extracorporeal Circuit

Potential Therapeutic

Applications:

• Cancer

• Life-threatening viral infections

• Organ Transplantation

5

Pipeline Targeting Multiple Indications

Indication

Pre-Clinical

Early Feasibility

Study

Oncology

Solid Tumors failing anti- PD-1

Expected to begin in Australia and India pending supporting data

Infections

India COVID-19

Ongoing

HCV

Completed

Single patient case study,

Viral

HIV

Completed

Emergency Use

COVID-19, Ebola

Organ Transplantation

Kidney

Pre-clinical Translational

Transplantation

Activities

6

The Rationale Exists For The Removal Of Tumor-derived Extracellular Vesicles By Aethlon's Hemopurifier® To Treat Cancer

Extracellular Vesicles (EVs) are small membrane-bound particles that serve as key mediators of cell-cell communication. They carry lipids, proteins, and nucleic acids, and are released by most cell types, including tumor cells.

Specifically, EVs and their cargo :

  • Have been shown to contribute to the spread of cancer (metastases)1
  • Play a role in immune system evasion by the tumor1
  • Facilitate chemotherapy resistance1
  • Interfere with antibody-based treatments (e.g., PD-1 antibody therapies such as Keytruda® and Opdivo®)2

We believe the removal of harmful EVs and their associated cargo may enhance existing cancer treatments

The Hemopurifier® has demonstrated clearance of EVs in vitro and in patients3

1. Zhang L, Yu D. Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):455-468.

2. Rasihashemi SZ, Gavgani ER, Majidazar R, et al. J Cell Physiol 2021:1-13.

7

3. Amundson DE, Shah US, de Necochea-Campion R, et al Front Med (Lausanne). 2021 Oct 8;8:744141.

In Vitro Removal Of Cancer-Derived EVs from Buffer Has Been Demonstrated1

  • Tumor derived EVs were isolated from cancer patient plasma and suspended in buffer
  • Samples were circulated over a scaled-down version of the Hemopurifier®
  • EV counts were quantified before and after passage over the scaled down device
  • The scaled down Hemopurifier was effective for clearing 92-99% of EVs suspended in buffer
  • Demonstrated capture of EVs from diverse tumor types including head and neck cancer, melanoma, ovarian cancer, esophageal cancer and breast cancer

Aethlon is exploring the therapeutic potential of removing tumor-derived

EVs in cancer patients with the Hemopurifier®

1. Marleau AM, Jacobs MT, Gruber N, et al. Cancer Res 2020;80 (16_Supplement):4509.

8

Clinical Development Plans Underway In Oncology

  • A new safety phase clinical trial in oncology is planned to include multiple tumor types, as well as dosing intervals, to help direct the development of Aethlon's Hemopurifier® as a treatment option in oncology
  • Aethlon has contracted with North American Science Associates, LLC (NAMSA), a major global contract research organization (CRO), to direct the planned oncology study in Australia and the U.S.
  • Aethlon has contracted with Qualtran LLC, a CRO focused on India, to direct the planned oncology trial in India
  • Interested sites have been identified in Australia and India with next step being Ethics Committee approvals in those countries
  • Aethlon needs to complete binding studies prior to the interested sites asking for Ethics Committee approvals

9

Recent Scientific & Clinical Literature Provides A Rationale For Hemopurifier Treatment In Severe COVID-19 Infections

  • COVID viremia is detected in ~34% of patients and is associated with severity, requirement for ICU stay, development of multi-organ failure and poor outcomes1
  • Direct viral injury to non-pulmonary organs has been noted in a COVID post-mortem study2
  • Viremia in COVID is associated with immune dysregulation, endothelial injury, coagulopathy and complement activation3
  • EVs and exosomal miRNAs may play a role in the spread of infection as well as ongoing inflammation, development of coagulopathy and lung injury4
  • Aethlon's proprietary Galanthus nivalis agglutinin (GNA) affinity resin has been shown to bind multiple clinically relevant SARS-CoV-2variants5

Demonstrated removal of SARS-CoV-2, EVs and miRNAs

in patients treated with the Hemopurifier®

1.Tang K, Wu L, Luo Y, Gong B.. J Med Virol. 2021 May;93(5):3165-3175.

  1. Deinhardt-EmmerS, Wittschieber D, et al. Elife. 2021 Mar 30;10:e60361.
  2. Bermejo-MartinJF, González-Rivera M, et al. Crit Care. 2020 Dec 14;24(1):691.
  1. Barberis E, Vanella VV, Falasca M, et al. Front Mol Biosci. 2021 Feb 22;8:632290.
  2. Gooldy M, Roux CM, LaRosa SP, et al. PLoS One. 2022 Jul 28;17(7):e0272377.

10

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Aethlon Medical Inc. published this content on 25 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2024 12:37:01 UTC.